• DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, June 06, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the Goldman Sachs 44^th Annual Global Healthcare Conference taking place on June 12^th – 15^th in Dana Point, CA. Daniel Tassé, Chief Executive Officer, will engage in a Fireside Chat session on Wednesday, June 14^th at 10:00am PST (1:00pm EST), as well as one-on-one investor meetings throughout the day.

A live webcast of the presentation will be available on the Investors & Media section of the Company’s website: DBV Technologies - 1617085 (webcasts.com).

A replay will also be available on DBV Technologies’ website for 90 days after the event.
        
About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Katie Matthews
DBV Technologies
+1 857-529-2563
katie.matthews@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com 

Viaskin and EPIT are trademarks of DBV Technologies.